Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 5,051 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule 2 Clear all
Terminated Phase 3 Interventional Results available

The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure

NCT00944229
View directory record Official record
Conditions
Heart Failure
Interventions
LOVAZA (Omega-3), Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

NCT01692301
View directory record Official record
Conditions
Hypertension
Interventions
LCZ696, Olmesartan, LCZ696 matching placebo, Olmesartan matching placebo, amlodipine, hydrochlorothiazide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
11
States / cities
Clearwater, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal

NCT00480441
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Dronabinol, BRENDA therapy, Placebo
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

NCT01129375
View directory record Official record
Conditions
Healthy
Interventions
clopidogrel, placebo, omeprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

NCT02195869
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Duarte, California • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin

NCT03211156
View directory record Official record
Conditions
Vaginitis Gardnerella
Interventions
Amoxicillin, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 30, 2026, 1:45 PM EDT
Not listed Not applicable Interventional

Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies

NCT03682029
View directory record Official record
Conditions
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-1, Cytopenia
Interventions
Vitamin C (ascorbic acid), Placebo
Dietary Supplement · Other
Lead sponsor
Copenhagen University Hospital, Rigshospitalet
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg Under Fasting Conditions

NCT01581866
View directory record Official record
Conditions
Healthy
Interventions
Ziprasidone Hydrochloride
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Results available

Respiratory Syncytial Virus - RSV Protocol

NCT01502072
View directory record Official record
Conditions
Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Pneumonia, Cancer, Acute Leukemia
Interventions
Ribavirin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer

NCT00348595
View directory record Official record
Conditions
Prostate Cancer
Interventions
Revlimid
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 4 Interventional Results available

rHGH and Intestinal Permeability in Intestinal Failure

NCT01380366
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Somatropin, Seven Day Food Diary, Blood Tests (standard of care), Fasting, Sugar Permeability Test, Urine Collection
Drug · Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

NCT01977651
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
Enzalutamide
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
Male only
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Anchorage, Alaska • Detroit, Michigan • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

NCT02987829
View directory record Official record
Conditions
Metastatic Castrate-resistant Prostate Cancer, Adenocarcinoma, Prostate
Interventions
TRC253
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions

NCT00759902
View directory record Official record
Conditions
Healthy
Interventions
morphine sulfate extended-release capsules, KADIAN (morphine sulfate extended-release) capsules
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia

NCT00569972
View directory record Official record
Conditions
Insomnia
Interventions
PD 0200390, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 3 Interventional

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

NCT00135395
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir+ritonavir, Lopinavir+ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
52
States / cities
Hobson City, Alabama • Montgomery, Alabama • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2010 · Synced Oct 30, 2026, 1:45 PM EDT
Terminated Phase 1 Interventional

A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome

NCT00676728
View directory record Official record
Conditions
Advanced or Refractory Leukemia, Myelodysplastic Syndromes
Interventions
JNJ-26481585
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 1 Interventional

Assess the Oral Bioavailability of New ABT-263 Formulations

NCT00743028
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Lymphomas, Leukemias
Interventions
ABT-263
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
5
States / cities
Encinitas, California • Santa Monica, California • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2010 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects

NCT01638442
View directory record Official record
Conditions
Healthy
Interventions
CHR-2797
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Early Phase 1 Interventional

Curcumin in Rheumatoid Arthritis

NCT00752154
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Curcumin (Longvida™)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Beverly Hills, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Protective Effects of EPI-743 on Noise-Induced Hearing Loss

NCT02257983
View directory record Official record
Conditions
Noise-induced Hearing Loss
Interventions
EPI-743, Placebo
Drug
Lead sponsor
Edison Pharmaceuticals Inc
Industry
Eligibility
18 Years to 30 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 30, 2026, 1:45 PM EDT
Recruiting Phase 2 Interventional

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

NCT05669846
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Healthy Donor Fecal Microbiota Transplant (hdFMT), Pembrolizumab
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 30, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

NCT01725126
View directory record Official record
Conditions
Obesity
Interventions
GSK2890457, Metformin, Placebo, Liraglutide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 30, 2026, 1:45 PM EDT
Terminated Phase 2 Interventional Results available

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

NCT00914940
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
Fludarabine Phosphate, Tacrolimus, Thiotepa, Total-Body Irradiation (TBI), Magnetic Affinity Cell Sorting, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, T Cell-Depleted Hematopoietic Stem Cell Transplantation
Drug · Radiation · Other + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
14 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 30, 2026, 1:45 PM EDT